Xromi

hydroxycarbamide · Lipomed GmbH
AUTHORISED IN THE EU

What Xromi is used for

Xromi is indicated for the prevention of vaso-occlusive complications of Sickle Cell Disease in patients over 9 months of age.

Approved use, as published by the European Medicines Agency.

Key facts

Brand
Xromi
Active substance
hydroxycarbamide
Disease area
Anemia, Sickle Cell
Medicine group
Antineoplastic agents
ATC code
L01XX05
Marketing authorisation holder
Lipomed GmbH
Authorised in the EU since
2019

Official information

Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.

Common questions

What is Xromi used for?

Xromi is indicated for the prevention of vaso-occlusive complications of Sickle Cell Disease in patients over 9 months of age.

What is the active substance in Xromi?

Xromi contains hydroxycarbamide.

Who makes Xromi?

The EU marketing authorisation holder is Lipomed GmbH.

Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.

← All specialty medicines, EU

For information only, not medical advice. This page is a plain-language summary written from standard prescribing information and the public guides linked below. Brands sometimes change their formula, so always check the composition printed on the pack. Doses here are typical adult doses; yours may differ. Do not start, stop or change a medicine without your doctor or pharmacist, and keep all medicines away from children. In an emergency, call 112 (India) or your local emergency number.